Guardian Capital Advisors LP Novo Nordisk A S Transaction History

Guardian Capital Advisors LP

  • $967 Million
  • Q3 2024

A detailed history of Guardian Capital Advisors LP transactions in Novo Nordisk A S stock. As of the latest transaction made, Guardian Capital Advisors LP holds 130,352 shares of NVO stock, worth $13.8 Million. This represents 1.6% of its overall portfolio holdings.

Number of Shares
130,352
Previous 129,766 0.45%
Holding current value
$13.8 Million
Previous $18.5 Million 16.2%
% of portfolio
1.6%
Previous 2.11%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$119.07 - $145.42 $69,775 - $85,216
586 Added 0.45%
130,352 $15.5 Million
Q2 2024

Aug 13, 2024
SELL
$122.71 - $146.91 $1.28 Million - $1.53 Million
-10,396 Reduced 7.42%
129,766 $18.5 Million
Q1 2024

May 14, 2024
SELL
$102.11 - $135.92 $1.16 Million - $1.55 Million
-11,371 Reduced 7.5%
140,162 $18 Million
Q4 2023

Feb 08, 2024
SELL
$87.78 - $105.45 $1.37 Million - $1.65 Million
-15,614 Reduced 9.34%
151,533 $15.7 Million
Q3 2023

Nov 13, 2023
BUY
$90.94 - $199.54 $7.46 Million - $16.4 Million
82,045 Added 96.41%
167,147 $15.2 Million
Q2 2023

Aug 14, 2023
SELL
$155.98 - $172.65 $2.74 Million - $3.04 Million
-17,586 Reduced 17.13%
85,102 $13.8 Million
Q1 2023

May 15, 2023
SELL
$132.34 - $159.14 $794,966 - $955,953
-6,007 Reduced 5.53%
102,688 $16.3 Million
Q4 2022

Feb 14, 2023
SELL
$102.55 - $135.33 $74,246 - $97,978
-724 Reduced 0.66%
108,695 $14.7 Million
Q3 2022

Nov 14, 2022
SELL
$95.28 - $116.93 $440,193 - $540,216
-4,620 Reduced 4.05%
109,419 $11.4 Million
Q2 2022

Aug 12, 2022
SELL
$103.24 - $121.81 $190,477 - $224,739
-1,845 Reduced 1.59%
114,039 $12.5 Million
Q1 2022

May 16, 2022
BUY
$93.1 - $112.54 $102,410 - $123,794
1,100 Added 0.96%
115,884 $13.6 Million
Q4 2021

Feb 10, 2022
SELL
$95.88 - $117.08 $495,699 - $605,303
-5,170 Reduced 4.31%
114,784 $11.6 Million
Q3 2021

Nov 15, 2021
SELL
$84.42 - $106.62 $38,326 - $48,405
-454 Reduced 0.38%
119,954 $11.6 Million
Q2 2021

Aug 17, 2021
BUY
$67.66 - $84.76 $206,024 - $258,094
3,045 Added 2.59%
120,408 $10.2 Million
Q1 2021

May 17, 2021
BUY
$67.06 - $75.82 $241,751 - $273,331
3,605 Added 3.17%
117,363 $8.28 Million
Q4 2020

Feb 12, 2021
BUY
$63.89 - $73.8 $170,266 - $196,677
2,665 Added 2.4%
113,758 $8.05 Million
Q3 2020

Nov 16, 2020
SELL
$63.69 - $70.22 $41,462 - $45,713
-651 Reduced 0.58%
111,093 $7.97 Million
Q2 2020

Aug 13, 2020
BUY
$58.54 - $67.94 $376,412 - $436,854
6,430 Added 6.11%
111,744 $5.35 Million
Q1 2020

May 15, 2020
BUY
$49.46 - $64.78 $35,363 - $46,317
715 Added 0.68%
105,314 $4.42 Million
Q4 2019

Feb 13, 2020
BUY
$49.86 - $58.26 $218,087 - $254,829
4,374 Added 4.36%
104,599 $6.23 Million
Q3 2019

Nov 14, 2019
BUY
$47.54 - $53.43 $272,641 - $306,421
5,735 Added 6.07%
100,225 $5 Million
Q2 2019

Aug 14, 2019
BUY
$46.79 - $52.47 $123,759 - $138,783
2,645 Added 2.88%
94,490 $4.94 Million
Q1 2019

May 15, 2019
BUY
$46.36 - $52.63 $398,927 - $452,881
8,605 Added 10.34%
91,845 $4.44 Million
Q4 2018

Feb 13, 2019
BUY
$41.54 - $47.25 $91,388 - $103,950
2,200 Added 2.71%
83,240 $3.88 Million
Q3 2018

Nov 13, 2018
BUY
$46.76 - $51.24 $59,619 - $65,331
1,275 Added 1.6%
81,040 $3.44 Million
Q2 2018

Aug 14, 2018
BUY
$44.29 - $50.42 $269,947 - $307,309
6,095 Added 8.27%
79,765 $3.95 Million
Q1 2018

May 15, 2018
BUY
$48.49 - $58.14 $46,065 - $55,233
950 Added 1.31%
73,670 $3.62 Million
Q4 2017

Feb 14, 2018
BUY
$47.53 - $53.73 $33,508 - $37,879
705 Added 0.98%
72,720 $4.2 Million
Q3 2017

Nov 15, 2017
BUY
$41.15 - $49.22 $78,390 - $93,764
1,905 Added 2.72%
72,015 $3.64 Million
Q2 2017

Aug 14, 2017
BUY
N/A
70,110
70,110 $2.99 Million

Others Institutions Holding NVO

# of Institutions
1,956
Shares Held
320M
Call Options Held
5.49M
Put Options Held
7.78M
View Full List

About NOVO NORDISK A S

NVO Quotes by TradingView
  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $239B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Guardian Capital Advisors LP Portfolio

Follow Guardian Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guardian Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Guardian Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email